Kia Nikoomanesh
Pulmonary Disease · Burbank, CANPI 1902260375
Payments from drug & device makers
What this record shows
This record is dominated by education: $12,079 of the $16,948 with a category attached, or 71.3%. Intuitive Surgical accounts for 86.2% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2023 at $12,884 and has fallen 94.6% since, to $694 in 2025.
Across 126 payments — averaging $134.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$15K
- GSK$421
- Baxter Healthcare$239
- Pulmonx Corporation$203
- Boehringer Ingelheim$175
- AstraZeneca$162
- plus $1K from 20 others
What the payments were for
- Travel & lodging$1,63110%
- Food & beverage$3,22919%
- Education$12,07971%
- Gifts$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 33 | $14,601 |
| GSK | 21 | $421 |
| Baxter Healthcare | 7 | $239 |
| Pulmonx Corporation | 6 | $203 |
| Boehringer Ingelheim | 7 | $175 |
| AstraZeneca | 7 | $162 |
| Sanofi | 6 | $143 |
| Actelion Pharmaceuticals US, Inc. | 5 | $122 |
| Exact Sciences | 4 | $110 |
| United Therapeutics Corporation | 4 | $104 |
| Novartis | 4 | $96 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Johnson & Johnson | 2 | $54 |
| Amgen | 2 | $52 |
| Viatris Specialty LLC | 2 | $51 |
| Paratek Pharmaceuticals, Inc. | 2 | $51 |
| Mylan Specialty L.p. | 2 | $43 |
| Philips North America LLC | 2 | $38 |
| Cook Medical LLC | 2 | $36 |
| AbbVie | 1 | $34 |
| Electromed, Inc. | 1 | $32 |
| Insmed, Inc. | 1 | $28 |
| Merck | 1 | $25 |
| Gilead | 1 | $19 |
| Chiesi USA, Inc. | 1 | $15 |
| Inogen, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$10,820
- ION$3,000
How this compares
$16,948 in reported general payments places this provider in the 85th percentile of 1,261 pulmonary disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $18,870 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 63 | $1,990 |
| Fluticasone Propionate | 12 | $76 |
| Furosemide | 16 | $30 |
| Prednisone | 19 | $27 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $421 | $18,87030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Burbank
- Daniel DeaBurbank$83K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.